A Chinese-developed Covid-19 vaccine candidate triggered a quick immune response in early trials, but the level of antibodies produced was below that of a person recovering from the disease, a study has shown.
一项研究显示，manbetx3.0 研制的一种新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）候选疫苗在早期试验中引发了快速的免疫反应，但其产生的抗体水平低于正在康复的新冠患者。
您已阅读12%（294字），剩余88%（2214字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。